
AstraZeneca PLC
AZNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 10, 2025 | HSBC | $108.00(-40%) | $179.64 | TheFly | |
| Dec 3, 2025 | Morgan Stanley | $103.00(-43%) | $180.34 | TheFly | |
| Jul 9, 2025 | Berenberg Bank | Luisa Hector | $97.00(-32%) | $141.64 | TheFly |
| Nov 13, 2024 | BMO Capital | Etzer Darout | $88.00(-46%) | $162.38 | StreetInsider |
| Sep 11, 2024 | BMO Capital | Etzer Darout | $89.00(-44%) | $159.88 | StreetInsider |
| May 30, 2024 | Argus Research | John Eade | $85.00(-45%) | $153.68 | StreetInsider |
| May 28, 2024 | BMO Capital | Etzer Darout | $82.00(-47%) | $153.48 | StreetInsider |
| Jul 12, 2023 | Leerink Partners | Andrew Berens | $79.00(-39%) | $129.72 | Benzinga |
| Jan 5, 2023 | BMO Capital | $82.00(-41%) | $139.00 | Benzinga | |
| Nov 11, 2022 | Leerink Partners | $78.00(-40%) | $130.18 | Benzinga | |
| May 4, 2022 | Leerink Partners | $75.00(-44%) | $134.34 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| UBS | upgrade | Neutral →Buy | Feb 13, 2025 |
| UBS | upgrade | Sell →Neutral | Nov 20, 2024 |
| Erste Group | upgrade | Hold →Buy | Sep 11, 2024 |
| TD Cowen | maintain | Buy | Aug 12, 2024 |
| Argus Research | maintain | Buy | May 30, 2024 |
| BMO Capital | maintain | Outperform | Apr 26, 2024 |
| Deutsche Bank | upgrade | Sell →Hold | Apr 16, 2024 |
| BMO Capital | maintain | Outperform | Feb 12, 2024 |
| Deutsche Bank | downgrade | Buy →Hold | Feb 8, 2024 |
| Jefferies | downgrade | Buy →Hold | Jan 3, 2024 |
| Jefferies | upgrade | Hold →Buy | Sep 25, 2023 |
| Erste Group | downgrade | Buy →Hold | Sep 8, 2023 |
| BMO Capital | maintain | Outperform | Aug 1, 2023 |
| Argus Research | maintain | Buy | May 26, 2023 |
| Argus Research | maintain | Buy | Apr 13, 2023 |
| SVB Leerink | maintain | Outperform | Nov 14, 2022 |
| SVB Leerink | maintain | Outperform | Nov 11, 2022 |
| Argus Research | upgrade | Hold →Buy | Aug 29, 2022 |
| SVB Leerink | maintain | Outperform | May 4, 2022 |
| SVB Leerink | maintain | Outperform | Feb 24, 2022 |
| DZ Bank | upgrade | Sell →Hold | Feb 11, 2022 |
| Jefferies | downgrade | Buy →Hold | Dec 7, 2021 |
| SVB Leerink | maintain | Outperform | Sep 27, 2021 |
| SVB Leerink | maintain | Outperform | Sep 20, 2021 |
| SVB Leerink | maintain | Outperform | Aug 4, 2021 |
Earnings History
Next report: Feb 9, 2027 · EPS est. $2.32| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 30, 2026 | $2.79 | $2.60 | $16.21B | $16.00B |
| Jul 27, 2026 | $2.63 | $2.50 | $15.38B | $15.44B |
| Apr 29, 2026 | $2.58 | $2.57 | $15.29B | $14.93B |
| Feb 10, 2026 | $2.12 | $2.09 | $15.50B | $15.44B |
| Nov 6, 2025 | $2.38 | $2.28 | $15.19B | $14.78B |
| Jul 29, 2025 | $2.18 | $2.18 | $14.46B | $14.10B |
| Apr 29, 2025 | $2.48 | $2.20 | $13.59B | $13.81B |
| Feb 6, 2025 | $2.10 | $2.07 | $14.89B | $14.23B |
News
AstraZeneca Plc (NYSE: AZN - Get Free Report) has received a consensus rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average 1 year price target
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
International Assets Investment Management LLC boosted its stake in AstraZeneca Plc (NYSE: AZN) by 1,564.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 28,785 shares of the company's stock after purchasing an additional 27,056 shares during the period. International Assets Investment Management LLC's holdings in
Bank Julius Baer and Co. Ltd Zurich bought a new stake in AstraZeneca Plc (NYSE: AZN) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,929,102 shares of the company's stock, valued at approximately $314,403,000. Bank Julius Baer and Co. Ltd
Total revenue grew 7% across the first nine months of 2026. AstraZeneca launched a $2 billion restructuring initiative through 2029.
AstraZeneca Plc (NYSE: AZN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $180.21 and traded as high as $188.39. AstraZeneca shares last traded at $186.49, with a volume of 5,464,384 shares traded. Key Headlines Impacting AstraZeneca Here are the key
Brian Low Financial Group LLC increased its position in shares of AstraZeneca Plc (NYSE: AZN) by 32.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,203 shares of the company's stock after buying an additional 3,491 shares during
AstraZeneca PLC (LON: AZN - Get Free Report) passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of £134.30 and traded as high as £140.02. AstraZeneca shares last traded at £139.96, with a volume of 40,274,711 shares changing hands. Trending Headlines about AstraZeneca Here are the key news
AstraZeneca PLC (AZN) Q3 2026 Earnings Call Transcript
AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, while loss-of-exclusivity pressures weighed on parts of its cardiovascular, renal and metabolism portfolio.
AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
AstraZeneca Plc (NYSE:AZN) on Friday posted better-than-expected third-quarter 2026 results. The European drug giant reported core earnings of $2.79 per share, beating the consensus of $2.59.
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AstraZeneca Chief Financial Officer Aradhana Sarin says the drug company uses AI in almost every aspect of the work they do. She talks beating on earnings, their drug pipeline and how the company approaches dealmaking.
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary 9M 2026 % Change Q3 2026 % Change $m Actual CER1 $m Actual CER - Product Sales 43,962 7 5 15,066 5 5 - Alliance Revenue 2,806 33 32 1,107 36 36 Product Revenue 46,768 8 6 16,173 7 7 Collaboration Revenue 113 22 23 36 >3x >3x Total Revenue 46,881 8 7 16,209 7 7 Reported EPS ($) 5.62 10 11 2.02 23 26 Core2 EPS ($) 8.00 14 14 2.79 17 19 Key performance elements for 9M 2026 (Growth numbers at constant exchange rates.
London's FTSE 100 looked on track to log its first monthly gain in three months, edging up on Friday as AstraZeneca rose, with investors welcoming a budget that was softer than expected on taxes.
The U.K. drugmaker reported net profit of $3.12 billion for the third quarter, up from $2.535 billion for the same period last year.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask about biomarker testing if they or a loved one is diagnosed with cancer, helping make biomarker testing a standard part of the cancer care conversation. Leaning into nostalgia for audiences who watched him early in his career, Mark-Paul acts as a warm, relatable guide showing how biomarker testing may.
After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well following a strong earnings beat. During the quarter, several key approvals and coverage expansions supported product growth for GH.